Table 2.

Risk of heart disease within 21 days after the first dose vaccination by vaccine type and COVID-19 with and without adjustment for confounding factors

	Univariable		Multivariable
	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
Vaccine Type
mRNA vaccinea	1.49 (1.39, 1.60)	<.0001	1.48 (1.35, 1.62)	<.0001
Othersb	Ref		Ref
COVID–19c
Yes	4.08 (1.31, 12.64)	0.0150	3.56 (1.15, 11.04)	0.0280
No	Ref		Ref
Sex
Male	0.96 (0.89, 1.02)	0.1681	0.97 (0.91, 1.04)	0.3623
Female	Ref		Ref
Age group
10–19	1.11 (0.93, 1.33)	0.2621	1.03 (0.86, 1.24)	0.7321
20–29	1.80 (1.61, 2.02)	<.0001	1.70 (1.51, 1.91)	<.0001
30–39	1.50 (1.35, 1.68)	<.0001	1.52 (1.36, 1.70)	<.0001
40–49	1.08 (0.96, 1.21)	0.1846	1.06 (0.95, 1.19)	0.3095
50–59	0.93 (0.84, 1.03)	0.1746	0.89 (0.80, 0.99)	0.0376
60–69	0.90 (0.81, 0.99)	0.0400	1.15 (1.02, 1.30)	0.0210
70+	Ref		Ref
Charlson comorbidity index
2+	1.26 (1.06, 1.48)	0.0071	1.44 (1.22, 1.71)	<.0001
1	1.02 (0.94, 1.11)	0.6380	1.13 (1.04, 1.24)	0.0063
0	Ref		Ref

^aThe mRNA vaccines consist of BNT162b2 and mRNA-1273.

^bOther vaccines include AZD1222 (AstraZeneca), JNJ-78436735 (Janssen), and NVX-CoV2373 (Novavax).

^cTime-varying covariate.